1-2 of 2
Nicola Melillo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese, Antonella Ciavolella, Ulisse Cucchi, Ivan Fraietta, Nicola Melillo, Francesco Fiorentini, Simona Rizzi, Matteo Salsa, Antonella Isacchi, Fabio Gasparri
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1465–1478.
https://doi.org/10.1158/1535-7163.MCT-23-0315
Published: 01 December 2023
View article titled, Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
Open the PDF for Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies in another window
Includes: Supplementary data
Journal Articles

Abstract A087: BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models

David H Peng, Antonio Tedeschi, Lorenz Herdeis, Fabio Savarese, Francesca Rocchetti, Popow Johannes, Heinrich J Huber, Nicola Melillo, Jake Dickinson, Hitesh B Mistry, Birgit Wilding, Matthias Treu, Julian Fuchs, Joachim Broker, Tobias Wunberg, Fiorella Schischlik, Jesse Lipp, Vandhana Ramamoorthy, Joseph R Daniele, Scott Kopetz, Michael Kim, Don L Gibbons, Christopher P Vellano, Joseph R Marszalek, Timothy P Heffernan, Darryl McConnell, Mark Pearson, Norbert Kraut, Dorothea Rudolph
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A087.
https://doi.org/10.1158/1535-7163.TARG-23-A087
Published: 01 December 2023
View article titled, Abstract A087: BI KRAS<sup>multi</sup>, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models